REGN
NASDAQ · Healthcare · Biotechnology · US
Research · Oct 31, 2026
Regeneron (REGN) Q3 2026 earnings: Dupixent profit share lifts operating income
Regeneron's Q3 2026 Sanofi profit share rose 77% to $2.575 billion after the development balance was repaid, and operating income nearly doubled to $2.048 billion.
Research · Oct 18, 2026
[REGN] Regeneron: Q3 2026 earnings preview on the Dupixent profit step-up and EYLEA HD
Regeneron's Q2 2026 revenue rose 17% to $4.29 billion, half from Sanofi's Dupixent profit share; Q3 tests whether a $253 million repaid deduction lifts operating income.
Research · Sep 29, 2026
Kodiak (KOD) Six-Month Wet AMD Data Raises the Bar for REGENXBIO (RGNX)
Kodiak's Zenkuda matched aflibercept in Phase 3 with 54% of patients on six-month dosing, resetting the bar that REGENXBIO's sura-vec gene therapy must clear in Q4 2026.
Research · Sep 3, 2026
[REGN] Regeneron Thesis 2026: Dupixent Crosses Into Rare Disease, Growth Sustains
Regeneron FY25 (Dec 31, 2025) at $14.34B revenue (+1%). NI $4.50B; EPS $41.48 (+8%). DUPIXENT $17.8B FY25 (+32% cc, partner-share); LIBTAYO $1.45B (+13% cc). Op margin compressed to 24.9% on R&D step-up + EYLEA biosimilar mix. FY26: R&D $5.9-6.1B, SG&A $2.5-2.65B, GM 83-84%. Initiated dividend $-370M.